New research released at the 2016 ASCO Annual Meeting



TITLE: EVALUATION OF TUMOR IMMUNE INFILTRATE AS A DETERMINANT OF RESPONSE TO NEO-ADJUVANT LAPATINIB AND TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER

De Angelis C1, Nagi C1, Hoyt C2, Linying2, Roman K2, Wang C2, Zheng Y2, Wang T1, Mao R1, Hilsenbeck SH1, Gutierrez C1, Wolff A3, Osborne, CK1, Rimawi MF1, Schiff R1
1Baylor College of Medicine, Houston, TX; 2PerkinElmer, Inc., Hopkinton, MA; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Abstract

Background: Dual HER2 blockade with LT without chemotherapy resulted in a substantial pathologic complete response (pCR) rate in HER2+ BC patients (pts) (TBCRC006). High levels of tumor infiltrating lymphocytes (TILs) at diagnosis have shown to be associated with greater benefit to T and chemotherapy in early-stage HER2+ BC pts. However the predictive value of TILs, TILs’ subsets, and other immune cells in pts receiving anti-HER2 treatment alone without chemotherapy is still unknown.

This poster highlights PerkinElmer’s NEW Opal™ Solid Tumor Immunology Panel kits. We’ve combined optimized sets of antibodies and detection reagents with verified protocols to provide the most direct route to biologically relevant results in your lab.

For more information on these kits, watch our short video
here.

Opal Multiplex IHC panels are a part of our Phenoptics™ Quantitative Pathology Research Solution for Cancer Immunology and Immunotherapy. Finally, there’s a complete in situ solution.

To view the entire poster, fill out our short form below